These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27740534)

  • 41. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
    Treiber G; Malfertheiner P
    J Clin Gastroenterol; 2005 Oct; 39(9):837-8; author reply 838. PubMed ID: 16145353
    [No Abstract]   [Full Text] [Related]  

  • 42. Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review.
    Cheng K; Ashby D; Smyth R
    J R Soc Med; 1997; 90 Suppl 31(Suppl 31):6-12. PubMed ID: 9204005
    [No Abstract]   [Full Text] [Related]  

  • 43. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Walker LJ; Newton J; Jones DE; Bassendine MF
    Hepatology; 2009 Jan; 49(1):337-8; author reply 338. PubMed ID: 19035342
    [No Abstract]   [Full Text] [Related]  

  • 44. Primary biliary cholangitis, let's try to keep the new nomenclature correct!
    Harinck F
    Neth J Med; 2016 Jul; 74(6):229-30. PubMed ID: 27571719
    [No Abstract]   [Full Text] [Related]  

  • 45. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom.
    Corpechot C; Poupon R
    Hepatology; 2007 Oct; 46(4):963-5. PubMed ID: 17894325
    [No Abstract]   [Full Text] [Related]  

  • 46. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 47. Triple therapy for patients with primary biliary cirrhosis with progressive disease despite ursodeoxycholic acid: another step forward.
    Kaplan MM; Bonis PA
    Gastroenterol Clin Biol; 2010; 34(4-5):239-41. PubMed ID: 20462715
    [No Abstract]   [Full Text] [Related]  

  • 48. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis.
    Kuiper EM; Hansen BE; Lesterhuis W; Robijn RJ; Thijs JC; Engels LG; Koek GH; Aparicio MN; Kerbert-Dreteler MJ; van Buuren HR;
    Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):29-33. PubMed ID: 20810227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre.
    Floreani A; Caroli D; Variola A; Rizzotto ER; Antoniazzi S; Chiaramonte M; Cazzagon N; Brombin C; Salmaso L; Baldo V
    Liver Int; 2011 Mar; 31(3):361-8. PubMed ID: 21059170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The characteristics of the use of ursodeoxycholic acid in chronic diseases of the hepatobiliary system].
    Dehtiar'ova II; Chernenko VV; Anokhina HA; Opanasiuk ND; Pavlik-Novol's'kyĭ T; Haĭsenko AV
    Lik Sprava; 1995; (9-12):47-8. PubMed ID: 8983789
    [No Abstract]   [Full Text] [Related]  

  • 51. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
    Stiefelhagen P
    MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
    [No Abstract]   [Full Text] [Related]  

  • 52. Reflections on therapeutic trials in primary biliary cirrhosis: a quality of life oriented counter-view.
    Jones DE; Bhala N; Newton JL
    Hepatology; 2006 Mar; 43(3):633; author reply 634. PubMed ID: 16496315
    [No Abstract]   [Full Text] [Related]  

  • 53. Methotrexate for primary biliary cirrhosis: who is to be trusted?
    Selmi C; Podda M
    Dig Dis Sci; 2010 Nov; 55(11):3013-5. PubMed ID: 20945095
    [No Abstract]   [Full Text] [Related]  

  • 54. Search for medical treatment for primary biliary cirrhosis.
    LaRusso N
    Lancet; 1997 Oct; 350(9084):1046. PubMed ID: 10213545
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of ursodeoxycholic acid on granulomatous liver disease due to sarcoidosis.
    Alenezi B; Lamoureux E; Alpert L; Szilagyi A
    Dig Dis Sci; 2005 Jan; 50(1):196-200. PubMed ID: 15712660
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical studies with silymarin: fibrosis progression is the end point.
    Schuppan D; Hahn EG
    Hepatology; 2001 Feb; 33(2):483-4. PubMed ID: 11172360
    [No Abstract]   [Full Text] [Related]  

  • 57. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.
    Ghonem NS; Boyer JL
    Hepatology; 2013 May; 57(5):1691-3. PubMed ID: 23174993
    [No Abstract]   [Full Text] [Related]  

  • 58. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study.
    Larghi A; Crosignani A; Battezzati PM; De Valle G; Allocca M; Invernizzi P; Zuin M; Podda M
    Aliment Pharmacol Ther; 1997 Apr; 11(2):409-14. PubMed ID: 9146783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fenofibrate treatment in patients with primary biliary cirrhosis.
    Ohira H; Sato Y; Ueno T; Sata M
    Am J Gastroenterol; 2002 Aug; 97(8):2147-9. PubMed ID: 12190200
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.